Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Healthcare Interactions
66%
Prostate Cancer
60%
Interleukin-15 (IL-15)
57%
Pancreatic Ductal Adenocarcinoma
57%
Contact Days
57%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
57%
T Cells
53%
Decedents
39%
Tumor
38%
Pembrolizumab
38%
Ultra-high
38%
CD8+ T Cells
36%
Immune Checkpoint Inhibitors
35%
Gastrointestinal Cancer
34%
Murine Model
34%
People with Cancer
31%
Microsatellite Instability-high (MSI-H)
30%
Ambulatory Care
28%
Parking Time
28%
Gastrointestinal Malignancies
28%
Service Type
28%
Cancer Clinical Trials
28%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
28%
Tribulation
28%
Cancer Drugs
28%
Thymocytes
28%
Local Metastasis
28%
Agonistic
28%
Pertuzumab
28%
Intravenous Formulation
28%
Promoter Elements
28%
Testicular Teratoma
28%
Trac
28%
Claudin-5
28%
T-bet
28%
Anti-CD40
28%
Adoptive Cell Therapy
28%
Functional Genomics
28%
Therapeutic Efficacy
28%
Interleukin-4 (IL-4)
28%
Forkhead Box Protein O1 (FOXO1)
28%
Tumor mutation Burden
28%
Exonuclease
28%
Polymerase
28%
Complement-mediated Injury
28%
Post-pubertal
28%
Potential Impact
28%
Subcutaneous Formulation
28%
MMR Deficiency
28%
Cancer-associated
28%
Immunology and Microbiology
T Cell
100%
Cytotoxic T-Cell
97%
Immunotherapy
61%
Interleukin 15
57%
Immune Checkpoint Inhibitor
57%
T Cell Receptor
46%
CD4
38%
T Cell Exhaustion
36%
T-Helper Cell
32%
Cell Function
32%
Programmed Death-Ligand 1
30%
Pertuzumab
28%
Next Generation Sequencing
28%
Immune Microenvironment
28%
DNA Polymerase
28%
Promoter Region
28%
Maturation
28%
Trastuzumab
28%
Thymocyte
28%
Human Leukocyte Antigen
28%
Immune Evasion
28%
Regulatory T Cell
28%
Immunostimulation
28%
Mutagenesis
28%
Chimeric Antigen Receptor T-Cell
28%
Prostate
28%
Denosumab
23%
Microsatellite Instability
23%
Genomic Instability
23%
Tumor Mutational Burden
19%
Immune Checkpoint Blockade
17%
Natural Killer Cell
16%
DNA Synthesis
14%
Mutational Load
14%
Pan-cancer
14%
Somatic Mutation
14%
Cell Population
12%
Major Histocompatibility Complex
11%
Cell Differentiation
11%
Pembrolizumab
9%
Lymphocyte
9%
MSH6
9%
CD8
9%
Mismatch Repair
9%
Ribonucleic Acid
9%
Interleukin 10
8%
Memory T Cell
7%
Precursor
6%
Antigenic Stimulation
6%
CD3 Antigen
6%
Medicine and Dentistry
Malignant Neoplasm
57%
Cancer
52%
Neoplasm
47%
Diseases
42%
Genetics
40%
Health Care
35%
Overall Survival
33%
Immunotherapy
32%
DNA Mismatch Repair
32%
T Cell
28%
Advanced Cancer
28%
Care Coordination
28%
Clinician
28%
Gastrointestinal Cancer
28%
Veterans Affairs
28%
Castration Resistant Prostate Cancer
28%
Pembrolizumab
28%
Graft Rejection
28%
FOLFOX
28%
Nivolumab
28%
Adenocarcinoma
28%
Germinoma
28%
Pancreas Transplantation
28%
Dentigerous Cyst
28%
Germ Cell
28%
Claudin 5
28%
Testis Teratoma
28%
Local Metastasis
28%
Functional Genomics
28%
Cell Therapy
28%
Interleukin 4
28%
Endothelial Cell
28%
Upregulation
28%
Prostate Cancer
24%
Infusion
21%
Tumor
14%
Ambulatory Care
14%
Small Intestine Obstruction
14%
Next Generation Sequencing
14%
Kidney Graft
14%
Fluorescence in Situ Hybridization
14%
Shared Decision Making
14%
Insulin Dependent Diabetes Mellitus
14%
Edema
14%
Tumor Mutational Burden
14%
Patient History of Kidney Transplantation
14%
Nodal Metastasis
14%
Folinic Acid
14%
Orchiectomy
14%
Cryptorchism
14%
